Patents by Inventor Simon Everitt

Simon Everitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20220340577
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 15, 2020
    Publication date: October 27, 2022
    Inventors: Andrew BAYLY, Matthew BLEICH, Jean-Damien CHARRIER, James DODD, Steven DURRANT, Meredith Suzanne ENO, Gorka ETXEBARRIA I JARDI, Simon EVERITT, Damien FRAYSSE, Shazia KELLY, Ronald KNEGTEL, Igor MOCHALKIN, Michael MORTIMORE, Kiri NORTH, Filippos PORICHIS, Robert PULLIN, Alistair RUTHERFORD, Pierre-Henri STORCK, Heather Clare TWIN
  • GCN2 inhibitors and uses thereof
    Patent number: 10988477
    Abstract: The present invention provides compounds inhibiting General amino acid Control Non-derepressible 2 kinase (“GCN2”), compositions thereof, and methods of using the same for treating various disorders, such as cancer.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: April 27, 2021
    Assignees: Merck Patent GmbH, Vertex Pharmaceuticals Incorporated
    Inventors: Andrew Bayly, Matthew Bleich, Jean-Damien Charrier, James Dodd, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Shazia Kelly, Ronald Knegtel, Igor Mochalkin, Michael Mortimore, Kiri North, Filippos Porichis, Robert Pullin, Alistair Rutherford, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20210040083
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 22, 2020
    Publication date: February 11, 2021
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • GCN2 inhibitors and uses thereof
    Patent number: 10793563
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: October 6, 2020
    Assignees: MERCK PATENT GMBH, VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20190233425
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 28, 2019
    Publication date: August 1, 2019
    Inventors: Andrew Bayly, Matthew Bleich, Jean-Damien Charrier, James Dodd, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Shazia Kelly, Ronald Knegtel, Igor Mochalkin, Michael Mortimore, Kiri North, Filippos Porichis, Robert Pullin, Alistair Rutherford, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20190233411
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 28, 2019
    Publication date: August 1, 2019
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 9499497
    Abstract: The present invention relates to compounds useful as inhibitors of indoleamine 2,3-dioxygenase (IDO). The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications. The compounds of this invention have formula I-A: wherein the variables are as defined herein.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: November 22, 2016
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Dean Boyall, Christopher Davis, James Dodd, Simon Everitt, Andrew Miller, Peter Weber, James Westcott, Stephen Young, Luca Settimo
  • COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
    Publication number: 20150376187
    Abstract: The present invention relates to pyrrolopyrazines compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Application
    Filed: June 24, 2015
    Publication date: December 31, 2015
    Inventors: Simon Everitt, Michael Paul Mortimore, Jean-Damien Charrier, Somhairle MacCormick, Pierre-Henri Storck, Ronald Knegtel, Joanne Pinder, Steven Durrant
  • COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20150336903
    Abstract: The present invention relates to compounds useful as inhibitors of indoleamine 2,3-dioxygenase (IDO). The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications. The compounds of this invention have formula I-A: wherein the variables are as defined herein.
    Type: Application
    Filed: May 27, 2015
    Publication date: November 26, 2015
    Inventors: Dean Boyall, Christopher Davis, James Dodd, Simon Everitt, Andrew Miller, Peter Weber, James Westcott, Stephen Young, Luca Settimo
  • Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
    Patent number: 9096602
    Abstract: The present invention relates to pyrrolopyrazines compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: August 4, 2015
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Simon Everitt, Michael Paul Mortimore, Jean-Damien Charrier, Somhairle MacCormick, Pierre-Henri Storck, Ronald Knegtel, Joanne Pinder, Steven John Durrant
  • Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 9073875
    Abstract: The present invention relates to compounds useful as inhibitors of indoleamine 2,3-dioxygenase (IDO). The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications. The compounds of this invention have formula I-A: wherein the variables are as defined herein.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: July 7, 2015
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Dean Boyall, Christopher Davis, James Dodd, Simon Everitt, Andrew Miller, Peter Weber, James Westcott, Stephen Young, Luca Settimo
  • AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES
    Publication number: 20150152103
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: February 5, 2015
    Publication date: June 4, 2015
    Inventors: Francesco Salituro, Luc Farmer, Randy Bethiel, Edmund Harrington, Jeremy Green, John Court, Jon Come, David Lauffer, Alex Aronov, Hayley Binch, Dean Boyall, Jean-Damien Charrier, Simon Everitt, Damien Fraysse, Michael Mortimore, Francoise Pierard, Daniel Robinson, Jian Wang, Joanne Pinder, Tiansheng Wang, Albert Pierce
  • Azaindoles useful as inhibitors of JAK and other protein kinases
    Patent number: 8987454
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: March 24, 2015
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Francesco Salituro, Luc Farmer, Randy Bethiel, Edmund Harrington, Jeremy Green, John Court, Jon Come, David Lauffer, Alex Aronov, Hayley Binch, Dean Boyall, Jean-Damien Charrier, Simon Everitt, Damien Fraysse, Michael Mortimore, Francoise Pierard, Daniel Robinson, Jian Wang, Joanne Pinder, Tiansheng Wang, Albert Pierce
  • AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES
    Publication number: 20140249138
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: February 18, 2014
    Publication date: September 4, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Francesco Salituro, Luc Farmer, Randy Bethiel, Edmund Harrington, Jeremy Green, John Court, Jon Come, David Lauffer, Alex Aronov, Hayley Binch, Dean Boyall, Jean-Damien Charrier, Simon Everitt, Damien Fraysse, Michael Mortimore, Francoise Pierard, Daniel Robinson, Jian Wang, Joanne Pinder, Tiansheng Wang, Albert Pierce
  • COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20140179699
    Abstract: The present invention relates to compounds useful as inhibitors of indoleamine 2,3-dioxygenase (IDO). The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications. The compounds of this invention have formula I-A: wherein the variables are as defined herein.
    Type: Application
    Filed: November 19, 2013
    Publication date: June 26, 2014
    Inventors: Dean Boyall, Christopher Davis, James Dodd, Simon Everitt, Andrew Miller, Peter Weber, James Westcott, Stephen Young
  • Azaindoles useful as inhibitors of JAK and other protein kinases
    Patent number: 8722889
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: May 13, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Francesco Salituro, Luc Farmer, Randy Bethiel, Edmund Harrington, Jeremy Green, John Court, Jon Come, David Lauffer, Alex Aronov, Hayley Binch, Dean Boyall, Jean-Damien Charrier, Simon Everitt, Damien Fraysse, Michael Mortimore, Francoise Pierard, Daniel Robinson, Jian Wang, Joanne Pinder, Tiansheng Wang, Albert Pierce
  • Compositions useful as inhibitors of protein kinases
    Patent number: 8669081
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: March 11, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Bebbington, Hayley Binch, Jean-Damien Charrier, Simon Everitt, Julian M.C. Golec, David Kay, Ronald Knegtel, Andrew Miller, Francoise Pierard
  • Compositions useful as inhibitors of protein kinases
    Patent number: 8642779
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative thereof, wherein A, B, Q, R1, and R2 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT or PDK1 kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds, and methods of utilizing those compositions in the treatment of various disorders.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: February 4, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Hayley Binch, Simon Everitt, Francesca Mazzei, Daniel Robinson
  • Aminopyrimidines useful as kinase inhibitors
    Patent number: 8637511
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: January 28, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Hayley Binch, Michael Mortimore, Chris Davis, Dean Boyall, Simon Everitt, Daniel Robinson, Sham Ramaya, Damien Fraysse, John Studley, Andrew Miller, Michael O'Donnell, Alistair Rutherford, Joanne Pinder
  • AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES
    Publication number: 20130345197
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: June 3, 2013
    Publication date: December 26, 2013
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Francesco Salituro, Luc Farmer, Randy Bethiel, Edmund Harrington, Jeremy Green, John Court, Jon Come, David Lauffer, Alex Aronov, Hayley Binch, Dean Boyall, Jean-Damien Charrier, Simon Everitt, Damien Fraysse, Michael Mortimore, Francoise Pierard, Daniel Robinson, Jian Wang, Joanne Pinder, Tiansheng Wang, Albert Pierce